估计阿尔茨海默病试验的社会经济地位
D M Rentz1, J D Grill, D P Molina-Henry
1Dorene M Rentz, PsyD, Department of Neurology, Brigham and Women's Hospital, 60 Fenwood Road, 9016S, Boston, MA 02115, USA, Email: drentz@bwh.harvard.edu, Telephone: 617-732-2385, FAX: 617-738-9122.
The journal of prevention of Alzheimer's disease
|October 1, 2024
概括
在临床试验中收集社会经济地位 (SES) 数据对于概括性至关重要. 一个经过修改的霍林斯黑德指数,与当前的职业更新,证明可行和有效的收集SES信息跨多样化的人口.
科学领域:
- 临床研究方法论临床研究方法论
- 卫生公平性健康公平性
- 社会医学科学 社会医学科学
背景情况:
- 社会经济地位 (SES) 指标在临床试验中收集不一致,阻碍了概括性评估.
- 这种数据缺口限制了对不同患者亚群的治疗疗效的理解.
- 标准化的SES数据收集对于公平的临床试验结果至关重要.
研究的目的:
- 调整和验证社会经济地位 (SES) 措施,用于临床试验.
- 将霍林斯黑德社会地位指数与当前的职业数据进行现代化.
- 建立一个标准化的方法,用于SES数据收集在多站点研究.
主要方法:
- 调整了霍林斯海德社会地位双因素指数,这是一个结合教育和职业指标.
- 更新了1965年职业名单,以反映2017年美国劳工统计局的职业数据.
- 在阿尔茨海默氏症临床试验联盟研究中实施了修订后的SES措施.
主要成果:
- 创建了一个经过修订的职业表.
- 在一项多站点临床试验中,使用修改后的霍林斯黑德指数收集SES数据的可行性得到证明.
- SES得分分布在所有阶层,表明其广泛适用性.
结论:
- 修改后的霍林斯黑德指数为SES数据收集提供了一个标准化的方法.
- 这种方法促进了临床试验中的数据聚合,监测和报告.
- 标准化的SES数据提高了试验结果的解释性和概括性.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170